Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Atara Biotherapeutics ( (ATRA) ) just unveiled an update.
On May 7, 2026, Atara Biotherapeutics announced that partner Pierre Fabre Pharmaceuticals had a constructive Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter issued on January 9, 2026 for the Biologics License Application of tabelecleucel (tab-cel). The FDA indicated that a single-arm study using an appropriate historical control, conducted in a pre-specified manner, could be considered an adequate and well-controlled trial to provide safety and efficacy data supporting a future marketing application for the proposed indication.
Pierre Fabre plans to submit an updated dataset with more patients and longer follow-up from the pivotal Phase 3 ALLELE study in adults and children aged two and older with relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after solid organ or hematopoietic cell transplant. Atara’s management said it will continue supporting Pierre Fabre in preparing the resubmission and expects to offer another regulatory update in the third quarter, signaling a clearer path but also ongoing regulatory work before potential U.S. market access for tab-cel.
The most recent analyst rating on (ATRA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
The score is held down primarily by weak financial quality (negative equity and ongoing negative free cash flow) and a broadly bearish technical trend (price below key moving averages with negative MACD). Valuation is difficult to support with a negative P/E and no dividend, while corporate events add notable listing and regulatory risks despite some near-term cash relief.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a T-cell immunotherapy company developing off-the-shelf, allogeneic Epstein-Barr virus (EBV) T-cell therapies for difficult-to-treat cancers and autoimmune diseases. Headquartered in Southern California and listed on Nasdaq as ATRA, Atara was the first company to gain regulatory approval for an allogeneic T-cell immunotherapy, building a portfolio that targets EBV-driven conditions.
Its platform avoids T-cell receptor and HLA gene editing, enabling rapidly deliverable cell therapies from inventory for patients following solid organ or hematopoietic cell transplants. The company partners with firms such as Pierre Fabre Pharmaceuticals to advance candidates like tabelecleucel (tab-cel) in relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
Average Trading Volume: 227,829
Technical Sentiment Signal: Sell
Current Market Cap: $43.84M
For detailed information about ATRA stock, go to TipRanks’ Stock Analysis page.